Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study

Table 1

Baseline demographics of the study subjects.

	Bromocriptine-QR treatment group ()	Reference group ()
Age (years)	46 ± 3	54 ± 3
Gender (% female)	88	40
Race	63% B; 25% H; 12% W	60% B; 40% H; 0% W
Weight (lbs)	252.3 ± 20	227.2 ± 17.4
BMI	46.2 ± 5.9	37.1 ± 5.3^*
Duration of diabetes (years)	13.7 ± 2.2	12.6 ± 3.5
HbA1c	9.74 ± 0.56	9.68 ± 0.74
Total daily dose of insulin (units)	199 ± 33	105 ± 41

^*Mean does not include one double amputee subject.
B: black; H: Hispanic; W: white; BMI: body mass index.